作为礼来在减肥药和糖尿病用药方面的竞争对手诺和诺德（NVO.US），在一天之前公布了2024年第4季业绩，其公布业绩后也在上涨，当前总市值为3,870亿美元。 减肥药至今依然是全球最火热的赛道，礼来和诺和诺德也是最受欢迎的减肥药巨头，在最新一季的业绩中，它们的减肥药有何出色的表现？我们来比较一下。

The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023 ... including Ozempic and Wegovy, remain on the FDA’s shortage list. Novo Nordisk recently ...

GlobalData recently predicted that Zepbound sales will top $25 billion by 2030, ahead of Wegovy with $19.4 billion, while the versions of the drug to treat diabetes – Mounjaro and Ozempic ...

Tirzepatide has been approved for treating type 2 diabetes under the trade name Mounjaro since May 2022 ... like Ozempic or Wegovy, Zepbound is also a GIP agonist. By activating this second ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio ... filled pen and Rybelsus oral tablet for type II diabetes and as Wegovy injection for weight management. On Wednesday, Novo Nordisk ...

Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...

Weight loss drugs like Ozempic and Wegovy cost an average of $1,083 per month if you pay full price ... For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...

Sales of GLP1 therapy tirzepatide marketed as Mounjaro for diabetes and Zepbound for weight loss reached $5.4 billion reflecting 128% year-over-year growth. Nonincretin revenue climbed 20% year ...